Dr. Robert Glanzman is a board-certified neurologist and Fellow of the American Academy of Neurology with over 20 years experience in neuroscience-related clinical development. Dr. Glanzman received his doctorate in medicine from Wake Forest University, trained in neurology at the University of Michigan and completed a fellowship in diagnostic nuclear medicine/PET imaging at Duke University.

Prior to joining industry, he held an appointment as Associate Clinical Professor of Neurology at Michigan State University. Since joining industry in 1999, Dr. Glanzman has held leadership roles at Pfizer, Novartis and Roche. While at Novartis he led the US, Phase 3 development of fingolimid (Gilenya®) for people with relapsing multiple sclerosis (MS), and while at Roche he designed and led the global Phase 3 development program for ocrelizumab (Ocrevus®) for people with both relapsing and primary progressive MS.

Over the past 10 years, Dr. Glanzman has served as Chief Medical Officer at biotechnology companies including Clene Nanomedicine, where he led a novel Phase 2 study in people with MS suffering from chronic optic neuropathy. Dr. Glanzman has authored numerous peer-reviewed publications.

• 

  Chief Medical Officer in Find Therapeutics

  Designing Ground-Breaking Therapies Bringing Hope